IPP Bureau
Piramal Phamra reports Q2 FY23 consolidated loss at Rs. 37.34 Cr
By IPP Bureau - November 09, 2022
Ami Organics Q2 FY23 revenue up 20.2%; Profit up 9%
By IPP Bureau - November 08, 2022
The company has successfully developed Methyl salicylate using Flow Chemistry and successfully erected a Flow reactor at Jhagadia plant and expects to start production from Q3 FY23
Vinati Organics consolidated Q2FY23 PAT up 43% at Rs. 116 Cr
By IPP Bureau - November 08, 2022
The company posted net profit of Rs.81.33 crores for the quarter ended September 30, 2021.
SeQuent Scientific to acquire 100% stake in Tineta Pharma
By IPP Bureau - November 08, 2022
The acquisition is for an enterprise value of Rs. 218 crores
Apollo Hospital launches Vertigo and Balance Disorder clinic in Hyderabad
By IPP Bureau - November 08, 2022
Zydus receives EIR with VAI from USFDA for Moraiya facility
By IPP Bureau - November 08, 2022
The USFDA has determined that the inspection classification of the facility is Voluntary Action Indicated (VAI)
Tatva Chintan Q2 FY23 revenue down 27%; Net profit down 78%
By IPP Bureau - November 07, 2022
Revenue from operations for the half year was Rs. 178.5 crore, declined by 23% whereas net profit for the half year was Rs. 16.9 crore, declined by 70%
IOLCP receives EDQM certification to supply Pantoprazole Sodium Sesquihydrate API in Europe
By IPP Bureau - November 07, 2022
Pantoprazole Sodium Sesquihydrate are proton pump inhibitors used in drugs to suppress the gastric acid secretion
Balaxi Pharmaceuticals delivers strong growth in Q2 FY23
By IPP Bureau - November 07, 2022
Revenue is up 23% whereas Profit After Tax expands 29% for the company
Lupin receives tentative approval from USFDA for Drospirenone Tablets
By IPP Bureau - November 07, 2022
Drospirenone Tablets (RLD Slynd) had estimated annual sales of US $141 million in the US
EMPA-KIDNEY trial showed significant benefit of Jardiance in reducing kidney disease progression
By IPP Bureau - November 07, 2022
Phase III trial also demonstrated a statistically significant reduction (14%) in hospitalization for any cause, bringing potential relief for patients and reducing burden on healthcare systems
Rossari Biotech Q2 FY23 revenue up 11%; Profit down 9%
By IPP Bureau - November 07, 2022
H1 FY23 revenues at Rs. 860.1 crore, higher by 40% YoY whereas PAT at Rs. 52.6 crore, higher by 4% YoY
Zydus Announces New Data Presentations at The Liver Meeting 2022
By IPP Bureau - November 04, 2022
Saroglitazar Mg is an investigational compound in the USA/EU, undergoing Phase 2b/3 clinical trials in patients with Primary Biliary Cholangitis and Phase 2b in patients with Non- alcoholic Steatohepatitis
GMM Pfaudler Q2FY23 consolidated profit up at Rs. 64.98 Cr
By IPP Bureau - November 04, 2022
The company has reported total income of Rs. 799.52 crores during the period ended September 30, 2022
Hester Biosciences Q2 FY23 consolidated profit up at Rs. 6.94 Cr
By IPP Bureau - November 04, 2022
The company has reported total income of Rs. 77.60 crores during the period ended September 30, 2022
